Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Receivables - Net (2017 - 2025)

Historic Receivables - Net for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $19.2 million.

  • Innate Pharma's Receivables - Net fell 4790.15% to $19.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $19.2 million, marking a year-over-year decrease of 4790.15%. This contributed to the annual value of $15.5 million for FY2024, which is 7835.73% down from last year.
  • Latest data reveals that Innate Pharma reported Receivables - Net of $19.2 million as of Q2 2025, which was down 4790.15% from $15.3 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Receivables - Net ranged from a high of $71.1 million in Q4 2023 and a low of $15.3 million during Q4 2024
  • In the last 5 years, Innate Pharma's Receivables - Net had a median value of $54.3 million in 2021 and averaged $48.1 million.
  • As far as peak fluctuations go, Innate Pharma's Receivables - Net soared by 3293.89% in 2023, and later crashed by 7851.74% in 2024.
  • Innate Pharma's Receivables - Net (Quarter) stood at $55.2 million in 2021, then fell by 3.04% to $53.5 million in 2022, then soared by 32.94% to $71.1 million in 2023, then plummeted by 78.52% to $15.3 million in 2024, then rose by 25.83% to $19.2 million in 2025.
  • Its Receivables - Net stands at $19.2 million for Q2 2025, versus $15.3 million for Q4 2024 and $36.9 million for Q2 2024.